Seagen touts PhII data for Adcetris/Opdivo combo; A-Alpha partners with Gilead on HIV
Seagen has revealed the data from Part C of a Phase II trial evaluating Adcetris in combination with Opdivo (nivolumab), a PD-1 inhibitor, as well …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
